BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27459899)

  • 21. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
    Ragulan C; Eason K; Fontana E; Nyamundanda G; Tarazona N; Patil Y; Poudel P; Lawlor RT; Del Rio M; Koo SL; Tan WS; Sclafani F; Begum R; Teixeira Mendes LS; Martineau P; Scarpa A; Cervantes A; Tan IB; Cunningham D; Sadanandam A
    Sci Rep; 2019 May; 9(1):7665. PubMed ID: 31113981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.
    Smith CG; Fisher D; Harris R; Maughan TS; Phipps AI; Richman S; Seymour M; Tomlinson I; Rosmarin D; Kerr D; Chan AT; Peters U; Newcomb PA; Idziaszczyk S; West H; Meade A; Kaplan R; Cheadle JP
    Clin Cancer Res; 2015 Aug; 21(15):3453-61. PubMed ID: 25873087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
    Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.
    Dunne PD; McArt DG; Bradley CA; O'Reilly PG; Barrett HL; Cummins R; O'Grady T; Arthur K; Loughrey MB; Allen WL; McDade SS; Waugh DJ; Hamilton PW; Longley DB; Kay EW; Johnston PG; Lawler M; Salto-Tellez M; Van Schaeybroeck S
    Clin Cancer Res; 2016 Aug; 22(16):4095-104. PubMed ID: 27151745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
    Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
    Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
    Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer.
    Mattesen TB; Rasmussen MH; Sandoval J; Ongen H; Árnadóttir SS; Gladov J; Martinez-Cardus A; Castro de Moura M; Madsen AH; Laurberg S; Dermitzakis ET; Esteller M; Andersen CL; Bramsen JB
    Nat Commun; 2020 Apr; 11(1):2025. PubMed ID: 32332866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Aasebø K; Bruun J; Bergsland CH; Nunes L; Eide GE; Pfeiffer P; Dahl O; Glimelius B; Lothe RA; Sorbye H
    Br J Cancer; 2022 Jan; 126(1):48-56. PubMed ID: 34671130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
    Smith CG; Fisher D; Claes B; Maughan TS; Idziaszczyk S; Peuteman G; Harris R; James MD; Meade A; Jasani B; Adams RA; Kenny S; Kaplan R; Lambrechts D; Cheadle JP
    Clin Cancer Res; 2013 Aug; 19(15):4104-13. PubMed ID: 23741067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CK7 and consensus molecular subtypes as major prognosticators in
    Loupakis F; Biason P; Prete AA; Cremolini C; Pietrantonio F; Pella N; Dell'Aquila E; Sperti E; Zichi C; Intini R; Dadduzio V; Schirripa M; Bergamo F; Antoniotti C; Morano F; Cortiula F; De Maglio G; Rimassa L; Smiroldo V; Calvetti L; Aprile G; Salvatore L; Santini D; Munari G; Salmaso R; Guzzardo V; Mescoli C; Lonardi S; Rugge M; Zagonel V; Di Maio M; Fassan M
    Br J Cancer; 2019 Oct; 121(7):593-599. PubMed ID: 31474758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.